Characteristics of the study population at the start of TMZ treatment and response to TMZ
| Characteristics . | Previous treatments . | TMZ treatment . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt . | Age (y) . | ISOLD score . | CSF tests . | Lines of previous treatment . | HD MTX . | HD cytarabine . | ITV MTX . | Ritux . | ASCT . | Other . | TMZ duration (mo) . | TMZ response . | PFS (mo) . | OS (mo) . | Vital status at last FU/ cause of death . |
| 1 | 53 | ND | Cy | 2 | First line × 3 | Second line × 2 | N | N | Second line/ C: TCB | N | 40 | CR | 115+ | 115+ | Alive in CR |
| 2 | 74 | 9.2 | ND | 3 | N | First line × 2 | Third line | Y (second line) | N | Second line: Ritux + idarubicin + ifosfamide | 5 | CR | 73+ | 73+ | Alive in CR |
| 3 | 81 | ND | Cy, Ck | 1 | N | N | First line | N | N | N | 3 | CR | 52+ | 52+ | Alive in CR |
| 4 | 85 | 18.8 | ND | 0 | N | N | N | N | N | N | 8 | CR | 47+ | 47+ | Alive in CR |
| 5 | 90 | 9.2 | ND | 0 | N | N | N | N | N | N | 6 | CR (cerebral and ocular) | 40 | 44 | Alive with relapse |
| 6 | 79 | 6.7 | Cy, Cl, Ck, F_ | 2 | First line × 6 | N | N | N | N | Second line ibrutinib | 25 | CR | 29+ | 29+ | Alive in CR |
| 7 | 75 | ND | ND | 4 | First line × 3 | Second line × 2 | Fourth line | Y (third line) | N | Third line: Ritux + idarubicin + ifosfamide | 5 | CR | 17 | 18 | Death due to cerebral progression |
| 8 | 72 | 11.4 | Cy | 1 | First line × 6 | First line × 2: dose reduction | N | N | N | N | 16 | CR | 16 | 30 | Alive with relapse |
| 9 | 87 | 18.8 | ND | 2 | N | N | First and second line | N | N | N | 5 | CR | 13 | 26 | Death due to cerebral progression |
| 10 | 73 | 15 | Cy, Cl | 2 | First line × 6 | First line × 2 | N | N | 2nd line/ C: TCB | Second line: ICE | 11 | CR | 11 | 14 | Death due to cerebral progression |
| 11 | 80 | 7.3 | Cy, Ck, F | 2 | First line × 6 | First line × 6 | N | N | N | Second line: ibrutinib | 10 | CR | 10 | 11 | Alive with relapse |
| 12 | 67 | 16 | Cy, F | 1 | First line × 6 | First line × 6 | N | N | N | N | 9+ | CR | 9+ | 9+ | Alive with CR |
| 13 | 56 | 6.6 | ND | 3 | N | First line × 4 | Second and third line | N | N | N | 8 | CR | 9 | 15 | Death due to cerebral progression |
| 14 | 70 | ND | ND | 1 | First line unknown doses | First line unknown doses | N | Y (first line) | N | N | 3 | CR | 6 | 43 | Alive with relapse |
| 15 | 75 | 12.9 | Cy | 2 | First line × 6 | First line × 2 | N | Y (first line) | N | Second line: lenalidomide | 5 | CR | 5 | 22 | Alive with relapse |
| 16 | 75 | ND | Cy | 1 | First line × 3 | First line × 2 | N | N | N | First line: cerebral Rx 11 Gy | 3 | PR | 11 | 81 | Alive with relapse |
| 17 | 44 | 16 | ND | 2 | First line × 5 | First line × 5 | N | N | N | Second line: ICE | 5 | PR | 5 | 28 | Alive with relapse |
| 18 | 74 | ND | Cy | 1 | First line × 6 | First line × 2 | N | N | N | N | 11 | PD | 11 | 16 | Lost to FU |
| 19 | 75 | 9.4 | Cy | 1 | First line × 6 | First line × 2 | N | N | N | N | 5 | PD | 3 | 17 | Death due to cerebral progression |
| 20 | 84 | ND | ND | 1 | First line × 6 | First line × 2 | N | N | N | N | Unknown | PD | 2 | 12 | Death due to unknown cause |
| 21 | 35 | ND | Cy | 1 | First line × 5 | N | N | N | N | N | 1 | PD | 2 | 21 | Lost to FU |
| Characteristics . | Previous treatments . | TMZ treatment . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt . | Age (y) . | ISOLD score . | CSF tests . | Lines of previous treatment . | HD MTX . | HD cytarabine . | ITV MTX . | Ritux . | ASCT . | Other . | TMZ duration (mo) . | TMZ response . | PFS (mo) . | OS (mo) . | Vital status at last FU/ cause of death . |
| 1 | 53 | ND | Cy | 2 | First line × 3 | Second line × 2 | N | N | Second line/ C: TCB | N | 40 | CR | 115+ | 115+ | Alive in CR |
| 2 | 74 | 9.2 | ND | 3 | N | First line × 2 | Third line | Y (second line) | N | Second line: Ritux + idarubicin + ifosfamide | 5 | CR | 73+ | 73+ | Alive in CR |
| 3 | 81 | ND | Cy, Ck | 1 | N | N | First line | N | N | N | 3 | CR | 52+ | 52+ | Alive in CR |
| 4 | 85 | 18.8 | ND | 0 | N | N | N | N | N | N | 8 | CR | 47+ | 47+ | Alive in CR |
| 5 | 90 | 9.2 | ND | 0 | N | N | N | N | N | N | 6 | CR (cerebral and ocular) | 40 | 44 | Alive with relapse |
| 6 | 79 | 6.7 | Cy, Cl, Ck, F_ | 2 | First line × 6 | N | N | N | N | Second line ibrutinib | 25 | CR | 29+ | 29+ | Alive in CR |
| 7 | 75 | ND | ND | 4 | First line × 3 | Second line × 2 | Fourth line | Y (third line) | N | Third line: Ritux + idarubicin + ifosfamide | 5 | CR | 17 | 18 | Death due to cerebral progression |
| 8 | 72 | 11.4 | Cy | 1 | First line × 6 | First line × 2: dose reduction | N | N | N | N | 16 | CR | 16 | 30 | Alive with relapse |
| 9 | 87 | 18.8 | ND | 2 | N | N | First and second line | N | N | N | 5 | CR | 13 | 26 | Death due to cerebral progression |
| 10 | 73 | 15 | Cy, Cl | 2 | First line × 6 | First line × 2 | N | N | 2nd line/ C: TCB | Second line: ICE | 11 | CR | 11 | 14 | Death due to cerebral progression |
| 11 | 80 | 7.3 | Cy, Ck, F | 2 | First line × 6 | First line × 6 | N | N | N | Second line: ibrutinib | 10 | CR | 10 | 11 | Alive with relapse |
| 12 | 67 | 16 | Cy, F | 1 | First line × 6 | First line × 6 | N | N | N | N | 9+ | CR | 9+ | 9+ | Alive with CR |
| 13 | 56 | 6.6 | ND | 3 | N | First line × 4 | Second and third line | N | N | N | 8 | CR | 9 | 15 | Death due to cerebral progression |
| 14 | 70 | ND | ND | 1 | First line unknown doses | First line unknown doses | N | Y (first line) | N | N | 3 | CR | 6 | 43 | Alive with relapse |
| 15 | 75 | 12.9 | Cy | 2 | First line × 6 | First line × 2 | N | Y (first line) | N | Second line: lenalidomide | 5 | CR | 5 | 22 | Alive with relapse |
| 16 | 75 | ND | Cy | 1 | First line × 3 | First line × 2 | N | N | N | First line: cerebral Rx 11 Gy | 3 | PR | 11 | 81 | Alive with relapse |
| 17 | 44 | 16 | ND | 2 | First line × 5 | First line × 5 | N | N | N | Second line: ICE | 5 | PR | 5 | 28 | Alive with relapse |
| 18 | 74 | ND | Cy | 1 | First line × 6 | First line × 2 | N | N | N | N | 11 | PD | 11 | 16 | Lost to FU |
| 19 | 75 | 9.4 | Cy | 1 | First line × 6 | First line × 2 | N | N | N | N | 5 | PD | 3 | 17 | Death due to cerebral progression |
| 20 | 84 | ND | ND | 1 | First line × 6 | First line × 2 | N | N | N | N | Unknown | PD | 2 | 12 | Death due to unknown cause |
| 21 | 35 | ND | Cy | 1 | First line × 5 | N | N | N | N | N | 1 | PD | 2 | 21 | Lost to FU |
Patient 12 is still receiving treatment with TMZ. Patients 6 and 8 were treated with MTX ITV for 2 months and lenalidomide for 5 months, respectively. ISOLD score was done in vitreous or AH; a score >4.6 has a 99% probability of LVRP. All patients tested for CSF were negative with all the tests used.
C, cerebral; CR, conditioning regimen; Cl, clonality; Ck, cytokine dosage; CR, complete response; Cy, cytology; F, flow cytometry; FU, follow-up; ICE, ifosfamide + carboplatin + etoposide; ITV, intravitreal; N, no; ND, no data; PD, progressive disease; PFS, progression-free survival; PR, partial response; Pt, patient; Ritux, rituximab; Rx, radiotherapy; OS, overall survival; SD, stable disease; TCB, thiotepa + cyclophosphamide + busulfan; Y, yes.